AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Praxis Precision Medicines stock falls 5.55% after mid-stage study results.
ByAinvest
Wednesday, Aug 13, 2025 11:02 am ET1min read
• Pomerantz LLP investigating claims against Praxis Precision Medicines. • Allegations of securities fraud or unlawful business practices. • Mid-stage study results for vormatrigine reported on August 4, 2025. • Treatment-emergent adverse events affected 36 of 61 patients. • 24% of participants discontinued the study. • Praxis stock price fell 5.55% to $51.09 per share.
New York, July 2, 2025 — Pomerantz LLP has initiated an investigation into claims on behalf of investors of Praxis Precision Medicines, Inc. (NASDAQ: PRAX). The investigation focuses on whether Praxis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices [1].On August 4, 2025, Praxis reported its financial results for the second quarter of 2025. Among the disclosed items, Praxis announced mid-stage study results for its anti-seizure medication vormatrigine. The study revealed that 36 out of 61 patients experienced treatment-emergent adverse events, and nearly one in four participants discontinued the study. This news led to a significant drop in Praxis's stock price, which fell $3.00 per share, or 5.55%, to close at $51.09 per share on August 4, 2025 [1].
Pomerantz LLP, known for its expertise in corporate, securities, and antitrust class litigation, is advising investors to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, to learn more about the investigation and how to potentially join the class action [1].
Investors should closely monitor this development as it could impact Praxis's financial health and regulatory outlook. The recent clinical results and their implications for the company's pipeline and stock price will continue to be a focus for investors and financial professionals.
References:
[1] https://www.marketscreener.com/news/pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc--ce7c5ed2d18cf725
[2] https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prax/praxis-precision-medicines/news/praxis-precision-medicines-prax-is-up-after-positive-phase-2
[3] https://www.globenewswire.com/news-release/2025/08/09/3130495/1087/en/INVESTOR-ALERT-Pomerantz-Law-Firm-Investigates-Claims-on-Behalf-of-Investors-of-Praxis-Precision-Medicines-Inc-PRAX.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet